Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias

Neurobiology of Aging

Volumn 33, Issue 9, 2012, Pages 2138-2144

  Gardoni, Fabrizio ^a   Sgobio, Carmelo ^b   Pendolino, Valentina ^b   Calabresi, Paolo ^b,c   Di Luca, Monica ^a   Picconi, Barbara ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Cell permeable peptides; Dopamine; Dyskinesias; NMDA receptor; Parkinson's disease; Striatum; Synaptic plasticity

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CENTRAL NERVOUS SYSTEM AGENTS; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; POSTSYNAPTIC DENSITY PROTEIN 95; TAT2A PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DYSKINESIA; HUMAN; NEUROMODULATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; RAT; SYNAPTIC POTENTIAL; SYSTEMIC THERAPY;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; GENE EXPRESSION REGULATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MEMBRANE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SUBCELLULAR FRACTIONS; TIME FACTORS;

EID: 84863439199     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.06.019     Document Type: Article

References (25)

1. Aarts M., Liu Y., Liu L., Besshoh S., Arundine M., Gurd J.W., Wang Y.T., Salter M.W., Tymianski M. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science 2002, 298:846-850.
2. Bard L., Sainlos M., Bouchet D., Cousins S., Mikasova L., Breillat C., Stephenson F.A., Imperiali B., Choquet D., Groc L. Dynamic and specific interaction between synaptic NR2-NMDA receptor and PDZ proteins. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19561-19566.
3. Birkmayer W., Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia [in German]. Wien. Klin. Wochenschr 1961, 73:787-788.
4. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther 1999, 290:1034-1040.
5. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010, 9:1106-1117.
6. Calabresi P., Maj R., Pisani A., Mercuri N.B., Bernardi G. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J. Neurosci 1992, 12:4224-4233.
7. Calon F., Rajput A.H., Hornykiewicz O., Bédard P.J., Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis 2003, 14:404-416.
8. Cenci M.A., Lee C.S., Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci 1998, 10:2694-2706.
9. Centonze D., Gubellini P., Picconi B., Calabresi P., Giacomini P., Bernardi G. Unilateral dopamine denervation blocks corticostriatal LTP. J. Neurophysiol 1999, 82:3575-3579.
10. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J. Med 1969, 280:337-345.
11. Gardoni F., Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur. J. Pharmacol 2006, 545:2-10.
12. Gardoni F., Mauceri D., Malinverno M., Polli F., Costa C., Tozzi A., Siliquini S., Picconi B., Cattabeni F., Calabresi P., Di Luca M. Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. J. Neurosci 2009, 29:669-677.
13. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., Calabresi P. A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J. Neurosci 2006, 26:2914-2922.
14. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., Brotchie J.M., Standaert D.G. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48:503-516.
15. Lange K.W., Kornhuber J., Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci. Biobehav. Rev 1997, 21:393-400.
16. Lau C.G., Zukin R.S. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat. Rev. Neurosci 2007, 8:413-426.
17. Lee E.A., Lee W.Y., Kim Y.S., Kang U.J. The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. Exp. Neurol 2003, 184:304-312.
18. Lim I.A., Merrill M.A., Chen Y., Hell J.W. Disruption of the NMDA receptor-PSD-95 interaction in hippocampal neurons with no obvious physiological short-term effect. Neuropharmacology 2003, 45:738-754.
19. Mercuri N.B., Bernardi G. The "magic" of L-dopa: why is it the gold standard Parkinson's disease therapy?. Trends Pharmacol. Sci 2005, 26:341-344.
20. Paillé V., Picconi B., Bagetta V., Ghiglieri V., Sgobio C., Di Filippo M., Viscomi M.T., Giampà C., Fusco F.R., Gardoni F., Bernardi G., Greengard P., Di Luca M., Calabresi P. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J. Neurosci 2010, 30:14182-14193.
21. Picconi B., Bagetta V., Ghiglieri V., Paille V., Di Filippo M., Pendolino V., Tozzi A., Giampa C., Fusco F.R., Sgobio C., Calabresi P. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 2011, 134:375-387.
22. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci 2003, 6:501-506.
23. Picconi B., Gardoni F., Centonze D., Mauceri D., Cenci M.A., Bernardi G., Calabresi P., Di Luca M. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J. Neurosci 2004, 24:5283-5291.
24. Picconi B., Paillé V., Ghiglieri V., Bagetta V., Barone I., Lindgren H.S., Bernardi G., Angela Cenci M., Calabresi P. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol. Dis 2008, 29:327-335.
25. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol 1996, 50(2-3):275-331.